snyderman nancy lynn MD has filed 29 insider transactions across 2 companies since June 2023.
Most recent transaction: a option exercise of 8013 shares of Alkermes plc. ($ALKS) on May 31, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 31, 2025 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 8013 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.00% |
| May 31, 2025 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Ordinary Shares | 8013 | $0.00 | 33,435.0000 | 169,198,000 | 31.52% | 0.00% |
| May 31, 2025 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1924 | $30.61 | 31,511.0000 | 169,198,000 | 5.75% | 0.00% |
| May 21, 2025 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 6142 | $0.00 | 6,142.0000 | 169,198,000 | 9999.99% | 0.00% |
| May 21, 2025 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 13474 | $0.00 | 13,474.0000 | 169,198,000 | 9999.99% | 0.01% |
| May 14, 2025 | Lyra Therapeutics, Inc. | $LYRA | snyderman nancy lynn MD | Not found | A | Restricted Stock Units | 32000 | $0.00 | 32,000.0000 | 65,880,561 | 9999.99% | 0.05% |
| June 29, 2024 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 6104 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.00% |
| June 29, 2024 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Ordinary Shares | 6104 | $0.00 | 26,887.0000 | 169,730,000 | 29.37% | 0.00% |
| June 29, 2024 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1465 | $24.10 | 25,422.0000 | 169,730,000 | 5.45% | 0.00% |
| June 13, 2024 | Lyra Therapeutics, Inc. | $LYRA | snyderman nancy lynn MD | Not found | A | Stock Option | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Restricted Stock Unit Award | 119 | $0.00 | 6,104.0000 | 163,742,000 | 1.99% | 0.00% |
| May 31, 2024 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 8013 | $0.00 | 8,013.0000 | 169,730,000 | 9999.99% | 0.00% |
| May 31, 2024 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 17492 | $0.00 | 17,492.0000 | 169,730,000 | 9999.99% | 0.01% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 448 | $24.55 | 22,848.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 548 | $46.72 | 27,948.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 324 | $46.72 | 16,524.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 284 | $57.11 | 14,484.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 350 | $44.75 | 17,850.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 256 | $16.52 | 13,079.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 230 | $18.45 | 11,739.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 313 | $24.24 | 15,990.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 231 | $30.86 | 11,785.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | J | Non Qualified Stock Option (Right to Buy) | 254 | $30.72 | 12,986.0000 | 163,742,000 | 1.99% | 0.00% |
| July 7, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Ordinary Shares | 5957 | $0.00 | 22,213.0000 | 163,742,000 | 36.64% | 0.00% |
| July 7, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | F | Ordinary Shares | 1430 | $29.88 | 20,783.0000 | 163,742,000 | 6.44% | 0.00% |
| July 7, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | M | Restricted Stock Unit Award | 5957 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| June 30, 2023 | Lyra Therapeutics, Inc. | $LYRA | snyderman nancy lynn MD | Not found | A | Stock Option | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| June 29, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Non Qualified Stock Option (Right to Buy) | 12732 | $0.00 | 12,732.0000 | 163,742,000 | 9999.99% | 0.01% |
| June 29, 2023 | Alkermes plc. | $ALKS | snyderman nancy lynn MD | Director | A | Restricted Stock Unit Award | 5985 | $0.00 | 5,985.0000 | 163,742,000 | 9999.99% | 0.00% |